ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
investment factor · long-only model fund

Foundry Healthcare NetEqFin Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FNEHHYPOTHETICAL MODEL
Since ’99
−78%
Expense Ratio
0.45%
placeholder
Holdings
91
cap-weighted
Inception
Jul 2022
placeholder
Full Sharpe
-0.04
Ann. Return (LS)
-1.1%
Ann. Volatility
28.8%
Max Drawdown
-87.5%
Test Sharpe ’19–26
-0.08
Test FF5 α (ann.)
-10.3%
vs Fama-French 5
Test FF5 α t-stat
-1.49
not significant
Monthly turnover
7%
of the long leg, per rebalance
Cumulative return (LS)
-78%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.58
what this fund holds
Long leg ann. return
8.4%
buyable, long-only
Long-short Sharpe
-0.04
requires shorting
Bottom bucket ann. return
9.4%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

91 of 91 · 100.0% of book
TickerCompanySectorMarket capWeight
1LLY
ELI LILLY & COHealthcare$1.11T
20.15%
2JNJ
JOHNSON & JOHNSONHealthcare$609.12B
11.06%
3ABBV
ABBVIE INCHealthcare$449.63B
8.16%
4UNH
UNITEDHEALTH GROUP INCHealthcare$386.95B
7.02%
5MRK
MERCK & CO INCHealthcare$314.90B
5.72%
6TMO
THERMO FISHER SCIENTIFIC INCHealthcare$197.88B
3.59%
7AMGN
AMGEN INCHealthcare$197.69B
3.59%
8ABT
ABBOTT LABORATORIESHealthcare$175.37B
3.18%
9GILD
GILEAD SCIENCES INCHealthcare$166.72B
3.03%
10DHR
DANAHER CORPHealthcare$144.26B
2.62%
11PFE
PFIZER INCHealthcare$142.77B
2.59%
12BMY
BRISTOL MYERS SQUIBB COHealthcare$124.04B
2.25%
13VRTX
VERTEX PHARMACEUTICALS INCHealthcare$123.26B
2.24%
14ISRG
INTUITIVE SURGICAL INCHealthcare$122.33B
2.22%
15MDT
MEDTRONIC PLCHealthcare$106.50B
1.93%
16MCK
MCKESSON CORPHealthcare$101.14B
1.84%
17HCA
HCA HEALTHCARE INCHealthcare$82.34B
1.49%
18ELV
ELEVANCE HEALTH INCHealthcare$80.92B
1.47%
19REGN
REGENERON PHARMACEUTICALS INCHealthcare$70.94B
1.29%
20EW
EDWARDS LIFESCIENCES CORPHealthcare$49.36B
0.90%
21IDXX
IDEXX LABORATORIES INCHealthcare$44.76B
0.81%
22BDX
BECTON DICKINSON & COHealthcare$43.58B
0.79%
23A
AGILENT TECHNOLOGIES INCHealthcare$37.13B
0.67%
24IQV
IQVIA HOLDINGS INCHealthcare$34.42B
0.62%
25RPRX
ROYALTY PHARMA PLCHealthcare$33.50B
0.61%
26ZTS
ZOETIS INCHealthcare$32.10B
0.58%
27DXCM
DEXCOM INCHealthcare$29.58B
0.54%
28RMD
RESMED INCHealthcare$28.86B
0.52%
29ILMN
ILLUMINA INCHealthcare$28.24B
0.51%
30MTD
METTLER TOLEDO INTERNATIONAL INCHealthcare$26.47B
0.48%
31WST
WEST PHARMACEUTICAL SERVICES INCHealthcare$25.31B
0.46%
32ROIV
ROIVANT SCIENCES LTDHealthcare$24.82B
0.45%
33DGX
QUEST DIAGNOSTICS INCHealthcare$23.32B
0.42%
34LH
LABCORP HOLDINGS INCHealthcare$23.24B
0.42%
35UTHR
UNITED THERAPEUTICS CORPHealthcare$22.74B
0.41%
36STE
STERIS PLCHealthcare$21.26B
0.39%
37THC
TENET HEALTHCARE CORPHealthcare$16.79B
0.30%
38BBIO
BRIDGEBIO PHARMA INCHealthcare$15.94B
0.29%
39MEDP
MEDPACE HOLDINGS INCHealthcare$15.36B
0.28%
40DVA
DAVITA INCHealthcare$15.21B
0.28%
41EXEL
EXELIXIS INCHealthcare$14.06B
0.26%
42ALGN
ALIGN TECHNOLOGY INCHealthcare$12.66B
0.23%
43RVTY
REVVITY INCHealthcare$12.29B
0.22%
44MOH
MOLINA HEALTHCARE INCHealthcare$11.74B
0.21%
45PODD
INSULET CORPHealthcare$11.36B
0.21%
46TECH
BIO-TECHNE CORPHealthcare$11.29B
0.20%
47EHC
ENCOMPASS HEALTH CORPHealthcare$11.13B
0.20%
48HSIC
HENRY SCHEIN INCHealthcare$10.00B
0.18%
49CORT
CORCEPT THERAPEUTICS INCHealthcare$9.72B
0.18%
50HALO
HALOZYME THERAPEUTICS INCHealthcare$9.23B
0.17%
51UHS
UNIVERSAL HEALTH SERVICES INCHealthcare$9.15B
0.17%
52ATR
APTARGROUP INCHealthcare$8.46B
0.15%
53TGTX
TG THERAPEUTICS INCHealthcare$8.40B
0.15%
54HQY
HEALTHEQUITY INCHealthcare$8.17B
0.15%
55LNTH
LANTHEUS HOLDINGS INCHealthcare$7.00B
0.13%
56CHE
CHEMED CORPHealthcare$6.77B
0.12%
57NVST
ENVISTA HOLDINGS CORPHealthcare$4.35B
0.08%
58DOCS
DOXIMITY INCHealthcare$3.94B
0.07%
59HAE
HAEMONETICS CORPHealthcare$3.54B
0.06%
60OPCH
OPTION CARE HEALTH INCHealthcare$3.41B
0.06%
61PGNY
PROGYNY INCHealthcare$2.50B
0.05%
62PBH
PRESTIGE CONSUMER HEALTHCARE INCHealthcare$2.36B
0.04%
63MD
PEDIATRIX MEDICAL GROUP INCHealthcare$2.15B
0.04%
64OMCL
OMNICELL INCHealthcare$2.09B
0.04%
65AUPH
AURINIA PHARMACEUTICALS INCHealthcare$2.05B
0.04%
66CDNA
CAREDX INCHealthcare$2.05B
0.04%
67ADMA
ADMA BIOLOGICS INCHealthcare$2.02B
0.04%
68ZYME
ZYMEWORKS INCHealthcare$1.77B
0.03%
69HCSG
HEALTHCARE SERVICES GROUP INCHealthcare$1.74B
0.03%
70ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.03%
71INSP
INSPIRE MEDICAL SYSTEMS INCHealthcare$1.46B
0.03%
72IRMD
IRADIMED CORPHealthcare$1.24B
0.02%
73NUTX
NUTEX HEALTH INCHealthcare$1.12B
0.02%
74CERT
CERTARA INCHealthcare$1.08B
0.02%
75PCRX
PACIRA BIOSCIENCES INCHealthcare$1.01B
0.02%
76TALK
TALKSPACE INCHealthcare$873M
0.02%
77AMPH
AMPHASTAR PHARMACEUTICALS INCHealthcare$871M
0.02%
78HSTM
HEALTHSTREAM INCHealthcare$832M
0.02%
79TCMD
TACTILE SYSTEMS TECHNOLOGY INCHealthcare$648M
0.01%
80FLGT
FULGENT GENETICS INCHealthcare$573M
0.01%
81ARVN
ARVINAS INCHealthcare$517M
0.01%
82XOMA
XOMA ROYALTY CORPHealthcare$504M
0.01%
83NRC
NRC HEALTHHealthcare$491M
0.01%
84VMD
VIEMED HEALTHCARE INCHealthcare$466M
0.01%
85ELMD
ELECTROMED INCHealthcare$349M
0.01%
86SPOK
SPOK HOLDINGS INCHealthcare$222M
0.00%
87UTMD
UTAH MEDICAL PRODUCTS INCHealthcare$222M
0.00%
88ANIK
ANIKA THERAPEUTICS INCHealthcare$203M
0.00%
89PDEX
PRO DEX INCHealthcare$183M
0.00%
90INFU
INFUSYSTEM HOLDINGS INCHealthcare$180M
0.00%
91JYNT
JOINT CORPHealthcare$127M
0.00%

Full long-leg book as of July 2026 · cap-weighted · total market cap $5.51T. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

91 classified
Value
Blend
Growth
Large
Mid
Small
14%10
46%28
39%19
<1%6
<1%5
<1%5
<1%5
<1%7
<1%4

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 100% toward Large, 63% toward Growth. Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt100% → Large
SmallLarge
Value ↔ growth tilt63% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 91 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
5
Failed
1
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    72.9%
    Margin
    -2.1%
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 91 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
0.9 (95% CI 0.7-1.1)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
8.8%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
0.92x
within
parametric
0.91x
within
cornish fisher
0.83x
within

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2006
Before publication (pre-2006)
-0.02
Sharpe · -0.8% p.a.
January 1999December 2006 · 96 mo
Since publication
-0.05
Sharpe · -1.2% p.a.
January 2007July 2026 · 235 mo
Change in Sharpe−0.03Sharpe weakened since publication

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
38%
10 of 26 3-year windows made money
Worst window
-0.54
Sharpe, January 2003 – December 2005
January 1999July 2026
Median Sharpe
-0.11
Dispersion
0.38
Best window
0.92

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.29.9%-27.2%
3 yearsp.a.9.1%-13.4%
5 yearsp.a.6.9%2.8%
10 yearsp.a.10.1%-5.2%
Since inceptionp.a.7.6%-5.3%
Calendar years
YearLong legLong-short
20267 mo6.6%-5.8%
202516.1%-26.4%
20242.2%-0.3%
20232.4%-10.3%
2022-0.2%44.6%
202125.7%56.7%
202014.0%-39.9%
201919.2%-23.6%
20187.4%36.0%
201720.8%-26.7%
2016-0.7%8.8%
20156.1%-3.6%
201421.6%-22.4%
201334.9%-13.8%
201219.1%-5.3%
20119.9%-2.1%
20102.1%-3.0%
200914.6%-5.3%
2008-21.7%14.2%
20076.0%6.0%
20065.2%-0.8%
20058.0%7.8%
20041.1%-4.9%
200315.3%-30.9%
2002-21.4%26.7%
2001-14.1%-4.6%
200043.8%-20.5%
1999-7.2%-28.9%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FNEH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2022-07-06 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$5.51T

Methodology

The Foundry Healthcare NetEqFin Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a NetEqFin signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.